Secondary prostate cancer


secondary prostate cancer

The hormone-sensitive cells die and the hormone-resistant cells overgrow, resulting in disease progression. The drug of choice for secondary treatment is estramustine Estracyt.

secondary prostate cancer

The success of the therapy is followed by changes of the prostate-specific antigen level and Karnofsky scale. In the present study, the results of estramustine treatment of 79 patients with advanced prostate cancer in 12 hospitals were evaluated.

secondary prostate cancer

The mean prostate-specific antigen level improved for 6 months, but rose from the ninth month on. The improvement in the subjective condition of the patients paralleled the change in the prostate-specific antigen level.

Clinical trials

The short time of improvement was a consequence secondary prostate cancer the very high prostate-specific antigen level and the poor general condition.

Estramustine administration is recommended when the prostate-specific antigen level becomes more than doubled following primary treatment.

secondary prostate cancer

If the prostate-specific antigen level has not decreased after treatment for 3 months, the secondary strategy is to apply chemotherapy. Publication types.

secondary prostate cancer